Live symbol workspace

XLV market intelligence

Chart context, AI evidence, sentiment, related news, and verified outcome history are grouped into one asset dossier.

Current $146.81

Trend Flat

Sentiment Neutral

{# Only render the live technical grid when the AI analysis carries real, non-placeholder data. Sentinel payloads (data_status error/collecting, current_price 0) are handled by the Asset Intelligence Dossier below, which degrades to a calm branded empty state instead of "0%" widgets. #}

Detailed Market Analysis

Key Levels

Support

$139.47

Resistance

$154.15

Volume & Momentum

Volume

Weak

0.8x avg

Momentum

0%

Weak

Technical Context

Current price

$146.81

RSI context

50

Market Sentiment

50

Neutral

Stock Metrics

Daily Vol

0%

VIX Est

20

Weekly

0%

Asset Intelligence Dossier

Over the last 30 days, AI sentiment for XLV skewed bullish (7 of 14 scored calls).

Provider track record

Not enough scored provider calls yet for this asset.

Confidence trend

30%

▼ 8.8 pts vs previous week

Avg confidence across 30 calls in the last 7 days

What sources say

Bullish 7 articles

3 Healthcare Stocks with Open Questions

Vanguard Health Care ETF vs State Street XLV: Which ETF Is the Better Buy for Investors in 2026?

State Street XLV vs VanEck BBH: Which Healthcare ETF Is the Better Buy in 2026?

Neutral 5 articles

Which Is the Better State Street Healthcare ETF: The Broad XLV or the Biotech XBI?

XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy?

XLV vs PBE: Is a Low-Cost Healthcare ETF the Better Buy Than a Focused Biotech Specialist?

Bearish 2 articles

State Street vs. First Trust: Is a Broad Healthcare or Biotech Focus Better for Your Portfolio?

PINK vs. XLV: How Do These Two Health Care ETFs Match Up?

Insider Trading

Refreshing insider trades from FinViz…

Technical Observations

Refreshing technical observations from FinViz...

XLV News Intelligence (32 articles)

AI-curated news influencing XLV price, sentiment, and trend

Explore All XLV News with AI Analysis

Economy

4 months, 2 weeks ago

1 Healthcare Stock on Our Watchlist and 2 We Find Risky

Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory …

Impact on XLV: The 2.2% decline in the healthcare industry has mirrored the S&P 500's …

The healthcare industry has experienced a 2.2% decline over the past six months, mirroring the … High (70%)

View full analysis →

Yahoo Finance 70% confidence

Stocks

4 months, 4 weeks ago

Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial

Pharmaceutical giant Pfizer and French partner Valneva on Monday said they planned to seek regulatory approval for a Lyme disease …

Impact on XLV: The announcement is likely to have a positive impact on Pfizer's (PFE) …

Pfizer and Valneva plan to seek regulatory approval for a Lyme disease vaccine after a … High (80%)

View full analysis →

MarketWatch 80% confidence